Deferred Tax Assets, Valuation Allowance of Avalo Therapeutics, Inc. from 31 Dec 2014 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Avalo Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2024.
  • Avalo Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $65,656,000, a 15% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Avalo Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $65,656,000 +$8,747,000 +15% 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q4 2023 $56,909,000 +$4,560,000 +8.7% 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q4 2022 $52,349,000 +$8,893,000 +20% 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q4 2021 $43,456,000 +$19,113,000 +79% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q4 2020 $24,343,000 +$10,000,995 +70% 31 Dec 2020 10-K 02 Mar 2022 2021 FY
Q4 2019 $14,342,005 +$3,616,869 +34% 31 Dec 2019 10-K 08 Mar 2021 2020 FY
Q4 2018 $10,725,136 +$6,701,146 +167% 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q4 2017 $4,023,990 -$26,850,541 -87% 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q4 2016 $30,874,531 +$6,548,157 +27% 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q4 2015 $24,326,374 +$4,833,415 +25% 31 Dec 2015 10-K 14 Mar 2017 2016 FY
Q4 2014 $19,492,959 31 Dec 2014 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.